Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASEL | Q05823 | 12/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25552948 | 0.94 | RNASEL (0.49) | RNASEL | |
| SCHEMBL25553043 | 0.92 | RNASEL (0.46) | RNASEL | |
| SCHEMBL25553177 | 0.91 | RNASEL (0.56) | RNASEL | |
| SCHEMBL20434842 | 0.88 | RNASEL (0.60) | RNASEL | |
| SCHEMBL25552992 | 0.88 | RNASEL (0.53) | RNASEL | |
| SCHEMBL21515851 | 0.88 | RNASEL (0.62) | RNASEL | |
| SCHEMBL21515887 | 0.88 | RNASEL (0.63) | RNASEL | |
| SCHEMBL27376664 | 0.87 | RNASEL (0.65) | RNASEL | |
| SCHEMBL27376774 | 0.87 | RNASEL (0.65) | RNASEL | |
| SCHEMBL25553141 | 0.87 | RNASEL (0.51) | RNASEL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158059-A1 | PREKALLIKREIN-MODULATING COMPOSITIONS AND METHODS OF USE THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158059-A1 | PREKALLIKREIN-MODULATING COMPOSITIONS AND METHODS OF USE THEREOF | KLKB1, PRKG1, PRKCH | RNASEL 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.